ReviewClinical pharmacology in drug development2017
Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date.
Review in Clinical pharmacology in drug development, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 70 citations in OpenAlex.
- Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial.BMC neurology · 2022Trial
- Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial.BMC neurology · 2021Trial
- Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1).Cephalalgia : an international journal of headache · 2020Trial
- Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).The journal of headache and pain · 2019Trial
- Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination.The journal of headache and pain · 2019Trial
- Safety Profile of Zavegepant in the Treatment of Acute Migraine: Insights from the FDA Adverse Event Monitoring System Database.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Migraine, monoclonal antibodies, and monitoring: a review of pharmacovigilance in the era of biologics.Frontiers in pharmacology · 2026Review
- Integrative Migraine Therapy: From Current Concepts to Future Directions-A Plastic Surgeon's Perspective.Medicina (Kaunas, Lithuania) · 2025Review
- Review
- Anti-CGRP mAbs for the Preventive Treatment of Migraine: An Overview Review and a Cost Saving Analysis in the Global Scenario.Hospital pharmacy · 2024Article
- CGRP Antagonism and Ketogenic Diet in the Treatment of Migraine.Medicina (Kaunas, Lithuania) · 2024Review
- Pediatric Migraines: A Comprehensive Review and Perspectives on Diagnosis and Treatment.Oman medical journal · 2023Review
- Managing migraine on the frontline: Identifying disease, understanding burden, and incorporating CGRP pathway-targeting therapies in primary care.British journal of pain · 2022Article
- A Comprehensive Review of Zavegepant as Abortive Treatment for Migraine.Health psychology research · 2022Review
- Roles of calcitonin gene-related peptide in the skin, and other physiological and pathophysiological functions.Brain, behavior, & immunity - health · 2021Review
- Erenumab Discontinuation After 12-Month Treatment: A Multicentric, Observational Real-Life Study.Neurology. Clinical practice · 2021Article
- Overcoming Obstacles in Protein Expression in the Yeast Pichia pastoris: Interviews of Leaders in the Pichia Field.Pacific journal of health (Stockton, Calif.) · 2021Article
- Calcitonin Gene-Related Peptide Monoclonal Antibody Versus Botulinum Toxin for the Preventive Treatment of Chronic Migraine: Evidence From Indirect Treatment Comparison.Frontiers in pharmacology · 2021Review
- Article
- Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.Advances in therapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine, a common neurovascular brain disorder, represents a severe and widespread health problem; along with medication-induced (medication-overuse) headache, it is the third-leading cause of disability worldwide. Currently, its therapeutic management remains unsatisfactory for several reasons; up to 40% of migraineurs are eligible for prophylactic treatment, but there are issues of efficacy, safety, and adherence. In recent years the evidence on the role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology has been consolidated, so new and promising treatments for migraine pain and its possible prevention have been developed. The following review reports the results of the clinical trials conducted so far with each of the new monoclonal antibodies targeting CGRP or its receptor, with particular reference to safety, tolerance, and efficacy in migraine prevention. Moreover, the pharmacological characterization and further developments of each monoclonal antibody are reported, based on current knowledge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.